Ayşe AYZIT KILINÇ, Canan AYGÜN, Metin SUNGUR, Kemal BAYSAL

Respiratory syncytial virus and effect of palivizumab prophylaxis in patients with congenital heart disease

Aim: We evaluated the prevalence of Respiratory syncytial virus (RSV), the rates of hospitalization and intensive care unit (ICU) admission due to RSV infection, the need for mechanical ventilation, and the efficacy of palivizumab prophylaxis in children with congenital heart disease (CHD).Material and Methods: A total of 419 patients under 2 years old who were hospitalized with lower respiratory tract infection (LRTI) were included in this study. Patients were divided into two groups according to the presence of CHD. 241 patients had unstable CHD and 178 patients had no underlying conditions. Palivizumab prophylaxis was administered to 29 of the patients with CHD and RSV infection; 22 of these patients were followed for 1 year.Results: RSV infection was detected in 19.5% of the patients with CHD and in 20% of those without CHD. Among the 241 patients with CHD and LRTIs, the rate and duration of hospitalization for RSV were 14% and 9.9 days, respectively. The rate of admittance to the ICU was 32% and that of mechanical ventilation was 19% in the CHD patients with RSV infection. Of the patients without CHD,12% were admitted to the ICU and 8% received mechanical ventilation. These rates were significantly higher among the RSV-infected patients with CHD. The rates of hospitalization for RSV before and after palivizumab prophylaxis were 59% and 14%, respectively; the difference was significant.Conclusion: RSV infection is a common cause of mortality and morbidity in patients with CHD; palivizumab prophylaxis is effective in these patients.

PDF

___

1. Hall CB, Weinberg GA, Iwane MK, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med 2009;360:588.
2. Nair H, Nokes DJ, Gessner BD, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 2010;375:1545.
3. Walsh EE, Hall CB. Respiratory syncytial virus. In: Diagnostic procedures for viral ,rickettsial and chlamydial infections. Eds: Schmidt NJ, Emmons RW. Sixth edition. American Public Association. Washington 1996:693-707.
4. Mac Donald N., Hall Caroline, Suffin Stephane: Respiratory syncytial virüs infection in infants with congenital heart disease, N.England J Med.1982;307:397-400.
5. Feltes TF, Groothuis JR. Acute and long-term effects of infection by the respiratory syncytial virus in children with congenital cardiac malformations. Cardiol Young 2005;15:266-73.
6. Gregson D, Lloyd T, Buchan S, et al. Comparison of the RSV Respi-Strip with Direct Fluorescent-Antigen Detection for Diagnosis of Respiratory Syncytial Virus Infection in Pediatric Patients. Journal of Clinical Microbiology 2005:5782-83.
7. Gullu E, Akin Y, Karaaslan A, et al. RSV infection in Istanbul: risk factors and frequency. J Infect Dev Ctries 2017;11:691-6.
8. Kanra G, Tezcan S, Yilmaz G, et al. Respiratory syncytial virus epidemiology in Turkey. Turk J Pediatr 2005;47:303-8.
9. Tatochenko V, Uchaikin V, Gorelov A, et al. Epidemiology of Respiratory Syncytial Virus in children < 2 years of age hospitalized with lower respiratory tract infections in the Russian Federation: a prospective, multicenter study. Clinical Epidemiology 2010:2,221-7.
10. Medrano C, Guerata L, Grueso J, et al. Respiratory infection in congenital cardiac disease. Hospitalizations in young children in Spain during 2004 and 2005: the CIVIC Epidemiologic Study. Cardiology Young 2007;17:360-71.
11. Altman C, Englund J, Feltes T, et al. Respiratory Syncytial Virus in Patients with Congenital Heart Disease: A contemporary look at epidemiology and success of preoperative screening. Pediatr Cardiol 2000; 21:433-8.
12. Bellavance M, Rohlicek CV,Bigras JL, et al. Palivizumab use among children with congenital heart disease in Quebec: Impact of Canadian guidelines on clinical practice. Paediatr Child Health 2006;11:19-23